| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Pathology and Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213 [W. L., D. K., R. D., M. J. B., A. C. G.]; Department of Pathology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908 [J-T. D., H. F. F.], and Department of Urology and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 [W. B. I., J. T. I.]
Previous studies demonstrated that CD44 is a metastasis suppressor gene for prostate cancer and that the expression of CD44 both at mRNA and protein levels is down-regulated during prostate cancer progression, with down-regulation being correlated with higher tumor grade, aneuploidy, and distant metastasis. In this study, we evaluated DNA hypermethylation as a potential mechanism accompanying this decreased CD44 expression in human prostate cancer. Nucleotide sequence analysis revealed a CpG island in the CD44 transcriptional regulatory region. We found that cytosine methylation of CD44 promoter occurs in CD44-negative prostate cancer cell line (i.e., LNCaP) but not in prostate cancer cell lines (i.e., TSU, PC3, and DU145) expressing this gene. In addition, we examined methylation status of CD44 in 84 matched normal and cancer prostate specimens. Hypermethylation of the 5' CpG island of CD44 gene was observed in 31 of 40 primary prostate cancer specimens, 3 of 4 distant organ site metastases obtained at autopsy from men died of prostate cancer, and 4 of the 40 matched normal tissues. These results demonstrated that methylation of the 5' CpG island of CD44 gene is closely associated with transcriptional inactivation, resulting in a decreased expression of CD44 in human prostate cancer.
This article has been cited by other articles:
![]() |
J. M. Yi, H.-C. Tsai, S. C. Glockner, S. Lin, J. E. Ohm, H. Easwaran, C. D. James, J. F. Costello, G. Riggins, C. G. Eberhart, et al. Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors Cancer Res., October 1, 2008; 68(19): 8094 - 8103. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. McCabe, D. D. Spyropoulos, D. Martin, and C. S. Moreno Genome-Wide Analysis of the Homeobox C6 Transcriptional Network in Prostate Cancer Cancer Res., March 15, 2008; 68(6): 1988 - 1996. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S Perry, R. Foley, K. Woodson, and M. Lawler The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Banine, C. Bartlett, R. Gunawardena, C. Muchardt, M. Yaniv, E. S. Knudsen, B. E. Weissman, and L. S. Sherman SWI/SNF Chromatin-Remodeling Factors Induce Changes in DNA Methylation to Promote Transcriptional Activation Cancer Res., May 1, 2005; 65(9): 3542 - 3547. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Nathoo, A Chahlavi, G H Barnett, and S A Toms Pathobiology of brain metastases J. Clin. Pathol., March 1, 2005; 58(3): 237 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-C. Li, P. R. Carroll, and R. Dahiya Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-k. Lee, J. W. Park, Y.-J. Kim, J. Kim, Y. Lee, J. Kim, and J.-S. Kim Toward a Functional Annotation of the Human Genome Using Artificial Transcription Factors Genome Res., December 1, 2003; 13(12): 2708 - 2716. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Jeronimo, R Henrique, P F Campos, J Oliveira, O L Caballero, C Lopes, and D Sidransky Endothelin B receptor gene hypermethylation in prostate adenocarcinoma J. Clin. Pathol., January 1, 2003; 56(1): 52 - 55. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Kang, B. F. Calvo, S. J. Maygarden, L. S. Caskey, J. L. Mohler, and D. K. Ornstein Dysregulation of Annexin I Protein Expression in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer Clin. Cancer Res., January 1, 2002; 8(1): 117 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsukura, K. Miyazaki, H. Yakushiji, A. Ogawa, K. Harimaya, Y. Nakabeppu, and M. Sekiguchi Expression and Prognostic Significance ofO6-Methylguanine-DNA Methyltransferase in Hepatocellular, Gastric, and Breast Cancers Ann. Surg. Oncol., December 1, 2001; 8(10): 807 - 816. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Cairns, M. Esteller, J. G. Herman, M. Schoenberg, C. Jeronimo, M. Sanchez-Cespedes, N.-H. Chow, M. Grasso, L. Wu, W. B. Westra, et al. Molecular Detection of Prostate Cancer in Urine by GSTP1 Hypermethylation Clin. Cancer Res., September 1, 2001; 7(9): 2727 - 2730. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F Costello and C. Plass Methylation matters J. Med. Genet., May 1, 2001; 38(5): 285 - 303. [Abstract] [Full Text] |
||||
![]() |
B. A. Yoshida, M. M. Sokoloff, D. R. Welch, and C. W. Rinker-Schaeffer Metastasis-Suppressor Genes: a Review and Perspective on an Emerging Field J Natl Cancer Inst, November 1, 2000; 92(21): 1717 - 1730. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Strobeck, M. F. DeCristofaro, F. Banine, B. E. Weissman, L. S. Sherman, and E. S. Knudsen The BRG-1 Subunit of the SWI/SNF Complex Regulates CD44 Expression J. Biol. Chem., March 16, 2001; 276(12): 9273 - 9278. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |